Navigation Links
Chindex-Fosun Pharma Joint Venture, Chindex Medical, To Participate in Acquisition of Alma Lasers; Fosun Pharma Increases Investment in Chindex Medical
Date:4/29/2013

BETHESDA, Md., April 29, 2013 /PRNewswire/ -- Chindex International, Inc. (NASDAQ: CHDX, "Chindex"), an American healthcare company providing healthcare services in China, today announced that Chindex Medical Limited ("CML"), its joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma"), has agreed to acquire approximately 36.17% of Alma Lasers, Inc. ("Alma") for approximately $53.5 million as part of a purchase by a group of buyers for substantially all of Alma. The buying group, which consists of CML, another subsidiary of Fosun Pharma and the Pramerica-Fosun China Opportunity Fund, would acquire substantially all of Alma indirectly through a jointly-owned entity. The total acquisition price by all buyers for Alma would be approximately $240 million, including indebtedness incurred at the Alma level, without recourse to CML.

In order to help fund the acquisition by CML of its interest in Alma, Fosun Pharma has agreed to invest approximately $41 million in cash in CML for additional equity in CML. Following such investment, CML, which currently is owned 51% by Fosun Pharma and 49% by Chindex, would be owned 70% by Fosun Pharma and 30% by Chindex. In connection with this investment Chindex has waived its participation in such investment and agreed to increase FosunPharma's board seats at CML from four of seven to five of eight.

Alma is a leading global medical energy-based (including lights, laser, radio frequency and ultrasonic) device manufacturer, with a comprehensive product offering and international sales network. Alma has developed leading R & D capabilities globally in the medical and aesthetic equipment manufacturing field and established a global brand in the market segment. Alma has an established record of sustained performance results. In 2012, Alma recorded nearly $100 million total revenue.

Roberta Lipson , President and CEO of Chindex and Director of CML, said, "We are pleased that Fosun Pharma's acquisition of Alma Lasers will benefit our CML joint venture. As a leading aesthetic device manufacturer, Alma is an ideal addition to CML's scope of specialized products and services and the acquisition represents an important step in its growth strategy.  We believe the Alma acquisition will contribute significant returns for Chindex and its shareholders over the long term."

About Chindex International, Inc.

Chindex is an American healthcare company providing healthcare services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics. United Family Healthcare currently operates in Beijing, Shanghai, Tianjin, Guangzhou and Wuxi. The Company also provides medical capital equipment and products through Chindex Medical Ltd., a joint venture company with manufacturing and distribution businesses serving both domestic China and export markets. With thirty years of experience, the Company's strategy is to continue its growth as a leading integrated healthcare provider in the Greater China region. Further company information may be found at the Company's website at http://www.chindex.com.

About Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Fosunpharma is a leading healthcare company in the PRC and primarily engaged in business segments including pharmaceutical manufacturing, pharmaceutical distribution and retail, healthcare services and diagnostic products and medical devices.

About Chindex Medical Limited

Chindex Medical Limited is a joint venture between FosunPharma and Chindex International, Inc., dedicated to bringing the world's leading edge healthcare technologies and products to China through the Company's national distribution infrastructure, while developing and manufacturing quality healthcare devices and consumables in China to serve the global marketplace. The Company provides comprehensive distribution services, including product registration, sales and marketing, clinical applications support and training, and technical service to numerous major multinational manufacturers of medical products.  The Company has particular expertise in successfully introducing novel and paradigm-changing technologies to China's healthcare marketplace, as well as in helping Chinese hospitals to access foreign-government sponsored financing in the form of loans and loan guarantees from the U.S. Export-Import Bank and the German KfW Development Bank.   With over 30 years of distribution experience and over 15 years of manufacturing experience, the Company's vision is to become a global leader in the healthcare market. 

About Alma Lasers

Alma Lasers, Inc. is a provider of laser, light-based and radiofrequency devices for aesthetic and medical applications. Alma Lasers remains dedicated to delivering innovative multitechnology/multi-application systems designed to meet the unique needs of today's practitioners. Alma's modular, cost-effective, high-performance systems enable practitioners to confidently offer state-of-the-art aesthetic treatments to their patients. Practitioners use Alma Lasers' products for non-invasive aesthetic procedures such as hair removal, acne treatment, wrinkle reduction, fractionated ablative and non-ablative skin resurfacing, vascular and pigmented lesions and leg vein treatments.

Safe Harbor Statement

Statements made in this press release relating to plans, strategies, objectives, economic performance and trends and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, the factors set forth under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, updates and additions to those "Risk Factors" in the Company's interim reports on Form 10-Q, Forms 8-K and in other documents filed by us with the Securities and Exchange Commission from time to time. Forward-looking statements may be identified by terms such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "forecasts," "potential," or "continue" or similar terms or the negative of these terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company has no obligation to update these forward-looking statements.

Contact:
ICR, Inc.
William Zima
(+86) 10-6583-7511
(646) 328-2510


'/>"/>
SOURCE Chindex International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmaceutical Market: Finland, Ireland, Denmark, Belgium, Cuba, Austria & Norway
2. Oramed Pharmaceuticals to Present Results of its Key Clinical Studies of Oral Insulin in Type 1 Diabetes Patients at the GTC Diabetes Summit, Boston, MA; April 29-30, 2013
3. Comprehensive Care Corporation Names Colonel Ramon Martinez President of CompCare Pharmacy Solutions, Inc.
4. Auxilium Pharmaceuticals Completes Acquisition Of Actient Holdings LLC To Create A Leading Urology Franchise With A Diversified Product Portfolio And Strong Growth Profile
5. Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication
6. Care Corporation Names Colonel Ramon Martinez President of CompCare Pharmacy Solutions, Inc.
7. Simcere Pharmaceutical Group Filed 2012 Annual Report on Form 20-F
8. Novartis Pharmaceuticals Corporation disputes allegations in two US Government lawsuits and looks forward to a fair discussion of the facts
9. National Association of Specialty Pharmacy (NASP) Appoints Thomas Blissenbach, RPh, MS as a Member of The Board of Directors
10. Pharmacy Benefits Academy Heads West, May 13-14 in Portland
11. Cannabis Science announces preclinical development program for CS-TATI-I, commencing EU operations in the Netherlands and sourcing proprietary material for pharmacokinetic characterization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... , April 27, 2016  Bayer Animal Health ... senior from the University of Florida College of ... Bayer Excellence in Communication Award (BECA). Brittany was ... were awarded a total of $70,000 in scholarship ... four years, Bayer has provided a total of ...
(Date:4/27/2016)... 27, 2016 Global  urinalysis ... billion by 2022, according to a new report ... (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... efficiency and accuracy delivered by the new generation ... novel urinalysis instruments and consumables. For instance, the ...
(Date:4/26/2016)... Hill-Rom Holdings, Inc. (NYSE: HRC ) ... Deutsche Bank 41 st Annual Health Care Conference on ... You are invited to listen to the live discussion via ... directly at http://edge.media-server.com/m/p/mr4uxgas . A recorded replay of the ... live event and accessible at the links above until August ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... 30, 2016 , ... “Aging well is a challenge for all of us, but there are things we can ... Kohli . “Research is showing more and more that there are simple, yet important steps ... as we age.” Top priorities Dr. Kohli’s recommends for her patients include;, , ...
(Date:4/29/2016)... ... 29, 2016 , ... Since launching its annual volunteer campaign ... the footwear industry, has broken all previous participation records in its first two ... states during the months of April and May, the 2016 Footwear Cares initiative ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... our nation’s productivity, stability, even security. Most importantly, employees are the single most ... why are American workers so unhappy? , Just under half of American workers ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... reveals that infants born with severe congenital diaphragmatic hernia have better survival rates ... with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, ...
(Date:4/29/2016)... ... April 29, 2016 , ... The Gluten-Free ... is pleased to announce the launch of the GFCP Scoop in ... more. The purpose of the GFCP Scoop site is to keep ...
Breaking Medicine News(10 mins):